Ranbaxy in pact with Zenotech on cancer drugs
Ranbaxy will market Zenotech's oncology cytotoxic injectable products under the Ranbaxy label in Latin America, Russia and other CIS markets.
BY OUR PHARMA CORRESPONDENT
March 25, 2006
Ranbaxy Laboratories Ltd, India's number one drugmaker, said it has entered into a strategic alliance Zenotech Laboratories on cancer
Under the terms of the semi-exclusive agreement, Ranbaxy will market the Hyderabad-based Zenotech's oncology cytotoxic injectable products under the Ranbaxy label in the key markets of Latin America, including Brazil and Mexico, along with Russia and other CIS markets.
Ranbaxy was also exploring the possibility of expanding the collaboration to include other markets. Zenotech will develop and manufacture the oncology products at the company's facilities in India.
Zenotech is a speciality generic injectables company with a biotech core. Its injectables product portfolio concentrates on niche therapy areas such as oncology, anaesthesiology, gynaecology and neurology. The company has a direct marketing presence in India and Vietnam, and has subsidiaries in Brazil and Nigeria. Zenotech's generic biologicals, GM-CSF and G-CSF, have completed clinical trials in India and are awaiting regulatory approvals.
The company has research and development facilities in India and the United States.
Ranbaxy commented that the agreement would enable it to enter a new therapeutic segment for it in the markets, and will enable the firm to continue strengthening its product portfolio and provide novel products. Ranbaxy already has a presence in the oncology segment in India, selling its oncology portfolio there through its Super Specialties division.
Zenotech added that the deal was beneficial for it because it would help it to expand its market reach in several emerging markets around the world. The alliance will help Zenotech speed up its biogenerics development programme.